News

Press Releases

Press lease

Katie Baumer
Communications and Social Media Manager, AAPS
+1.703.248.4772 direct
+1.407.685.4009 Press Room
BaumerK@aaps.org
2015-10-25

AAPS Announces 2015 Fellows

Embargoed until:                                                       
Oct. 25, 4:30 p.m. EST

Honored at Annual Meeting and Exposition for Outstanding Contributions to the Pharmaceutical Sciences  

ORLANDO, Fla.—The American Association of Pharmaceutical Scientists (AAPS) is pleased to announce its 2015 AAPS Fellows. AAPS Fellows are granted the honor each year for making sustained remarkable scholarly and research contributions to the pharmaceutical sciences such as original articles, scientific presentations at AAPS Annual Meeting and Expositions, and/or patents.

Jörg Breitkreutz, Ph.D. | Heinrich-Heine-University, Germany

Dr. Breitkreutz is a professor for pharmaceutical technology and biopharmacy and the director of the Institute of Pharmaceutics and Biopharmaceutics at the Heinrich-Heine-University in Düsseldorf, Germany. Presently, he is the president of the International Association of Pharmaceutical Technology (APV) located in Germany. His research focuses on the development of patient-centered medicinal products and medical devices for children and the elderly.

Rosalinde Masereeuw, Ph.D. | Utrecht Institute for Pharmaceutical Sciences, the Netherlands

Dr. Rosalinde (Roos) Masereeuw is a full professor of Experimental Pharmacology at the Utrecht Institute for Pharmaceutical Sciences in the Netherlands. Research performed by her group is designed to find novel therapeutic strategies to improve kidney function in renal disorders. Her group has developed unique human renal cell lines with a high predictive value for renal drug excretion and metabolism. These cell lines are used in the development of a bioartificial kidney and a kidney-on-a-chip device suitable for toxicity testing of potential nephrotoxic compounds.

Samir Mitragotri, Ph.D. | University of California, Santa Barbara

Biopharmaceutical drugs such as insulin, vaccines and growth hormones are delivered by injections. Injections have several limitations including pain, needle-phobia, and misuse. Professor Samir Mitragotri has developed technologies to deliver these drugs without using needles through the skin. Skin is the body’s natural barrier and prevents entry of drugs. Professor Mitragotri created devices and formulations that safely open the skin to allow passage of drugs. His technologies allow delivery of drugs to treat various diseases including diabetes, cancer, and infections.

Steven P. Schwendeman, Ph.D. | University of Michigan

Dr. Steve Schwendeman is the Ara G. Paul Professor and Chair of Pharmaceutical Sciences and Professor of Biomedical Engineering at the University of Michigan, as well as the Associate Editor of the Journal of Controlled Release. His primary scientific contribution is related to his work with biodegradable poly(lactic-co-glycolic acid), or PLGA. His work has demonstrated that PLGA, which allows drugs to slowly release in the body over a course of weeks and/or months, can prevent damage of lage and sensitive protein drug molecules. His research also describes the complex physical chemistry occurring in PLGA and how to place proteins inside the PLGA without using protein-damaging oil-based solvents. He is the first scientist to show how tiny holes in PLGA spontaneously close and how this healing then affects the release of drugsfrom the dosage form right after administration to patients.

Gopi Shankar, Ph.D., M.B.A. | Johnson & Johnson

Dr. Gopi Shankar is a senior director at Janssen BioTherapeutics (a division of Johnson & Johnson), where he heads the Bioanalytical Sciences & Immunogenicity Department. Biological drugs, manufactured in living organisms, are a highly effective class of drugs, but can sometimes produce vaccine-like effects in which the body develops antibodies (immunogenicity) to resist the drug, or other medical consequences. A world-renowned expert in the field of immunogenicity, Dr. Shankar has published in the areas of basic immunological research and technical, strategic and regulatory best practices. He is a prominent member of the American Association of Pharmaceutical Scientists (AAPS) and has led or contributed to several high-impact  scientific advances in immunogenicity, including six industry whitepapers and a chapter in the United States Pharmacopeia.  His research, consensus-building efforts and best-practice publications, both independently and through AAPS, have transformed the thinking and tactical processes related to immunogenicity around the globe.

Sven Stegemann, Ph.D. | Capsugel and Graz University of Technology

Dr. Sven Stegemann is director, pharmaceutical business development at Capsugel, and professor of patient centric drug design and manufacturing at the Graz University of Technology, Austria. Over the course of his 18-year career at Capsugel, Dr. Stegemann has worked as an advisor to major pharmaceutical companies on ways to improve the design, development and manufacture of pharmaceutical products so they better address the individual needs of patients. In his academic role, Dr. Stegemann focuses his research on the rational development of patient centric drug products and their associated manufacturing technologies, as well as the education and training of students and young scientists. Dr. Stegemann is the founder and chair of the AAPS Focus Group on Patient-Centric Drug Development, Product Design, and Manufacturing as well as the founder and President of the Geriatric Medicine Society.

Julie A. Stone, Ph.D. | Merck Research Laboratories

Dr. Julie Stone is a research scientist at Merck Research Laboratories.  Over a 20-year career, her research has focused on the use of computer modeling and simulation to enhance decision making in drug discovery and development, a scientific field known as pharmacometrics. Models integrate diverse data from laboratory testing to clinical trials results with biologic knowledge to aid interpretation of results and through model-based simulations to predict response beyond the specific tested conditions. These approaches provide valuable insights to inform the right biologic target, molecule, dose, treatment paradigm and patient population to optimize benefit and reduce risk from a therapeutic intervention under research evaluation. Dr. Stone has applied these approaches in a variety of disease areas including HIV, HCV, oncology, diabetes, osteoporosis, and Alzheimer’s disease, and through these efforts has contributed to the development and approval of 11 Merck medicines.

Allen C. Templeton, Ph.D. | Merck and Company, Inc.

Dr. Templeton is a scientific researcher and leader in drug development at Merck Research Laboratories. Dr. Templeton’s research is focused on finding ways to deliver medicine to patients in effective, high quality, cost-effective and convenient ways. Many diseases require specialized and advanced drug delivery approaches in order for the drug to reach the target site of the disease within the body. These novel dosage forms require advanced technology and research in order to ensure that they work as intended, have appropriate shelf-life and quality, and can be manufactured in reproducible and cost-effective ways. Dr. Templeton and his group are pioneers seeking to extend the boundaries of drug delivery research in order to bring new, life-saving medicines to patients in diverse fields such as oncology, infectious diseases and neurosciences.

# # #

About AAPS: The American Association of Pharmaceutical Scientists (AAPS) is a professional, scientific organization of approximately 10,000 members employed in academia, industry, government, and other research institutes worldwide. Founded in 1986, AAPS advances the capacity of pharmaceutical scientists to develop products and therapies that improve global health. Visit www.aaps.org today. Follow us on Twitter @AAPSComms; official Twitter hashtag for the meeting is: #AAPS2015.